Romiplostim use in immune thrombocytopenia: Experience in Cuenca, Ecuador
Abstract
Introduction. The international consensus and the American Society of Hematology guidelines from 2019 established thrombopoietin analogues as the second-line therapy for primary immune thrombocytopenia cases.
Objectives. To describe romiplostim usefulness in patients with immune thrombocytopenia in a third-level hospital in Cuenca, Ecuador.
Materials and methods. We conducted a descriptive and retrospective study in patients with immune thrombocytopenia treated with romiplostim. We evaluated the following variables: age, gender, previous therapies to romiplostim, dose, frequency, complications, change of thrombopoietin analogue, and treatment discontinuation.
Results. We included 21 patients with immune thrombocytopenia treated with romiplostim, with a median age of 49 years. All patients received corticosteroids as first-line treatment. Three patients required longer administration intervals (over a week), with weekly doses lower than those recommended (< 1 μg/kg). Due to lack of efficacy, six patients replaced elthrombopag with romiplostim. Of the total, three suffered thrombotic complications: two had portal venous thrombosis, and one had pulmonary thromboembolism; five of the patients discontinued romiplostim scheme without resuming it.
Conclusions. Romiplostim constitutes a convenient second-line therapy in immune thrombocytopenia. Despite the small sample size, romiplostim early use can minimize
toxicities and infectious risks.
Downloads
References
Álvarez-Román MT, Berrueco-Moreno R, Canaro-Hirnyk M, Entrena-Ureña L, Fernández-Fuertes F, González-López T, et al. Directrices de diagnóstico, tratamiento y seguimiento de la PTI. Recomendaciones del Grupo de Trabajo de la SEHH y GEPTI. Primera edición. Madrid: Sociedad Española de Hematología y Hemoterapia; 2020.
Zychowicz A, Radkowiak, D Lasek A, Malczak P, Witowsky J, Major P, et al. Laparoscopic splenectomy for thrombocytopenia immune in patients with a very low platelet count. Videosurgery Miniinv. 2018;13:157-63. https://doi.org/10.5114/wiitm.2018.75847
Deshayes S, Khellaf M, Zarour A, Layese R, Fain O, Terriou L, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. Am J Hematol. 2019;94:1314-24. https://doi.org/10.1002/ajh.25632
González-Porras J, Godeau B, Carpenedo M. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719837906. https://doi.org/10.1177/2040620719837906
Álvarez-Román MT, Fernández-Bello I, Arias-Salgado EG, Rivas-Pollmar MI, Jiménez-Yuste V, Martín-Salces M, et al. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Thromb Haemost. 2014;112:65-72. https://doi.org/10.1160/TH13-10-0873
Provan D, Arnold D, Bussel J, Chong B, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780-817. https://doi.org/10.1182/bloodadvances.2019000812
Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel J. Thrombopoietin receptor agonists: Ten years later. Haematologica. 2018;104:1112-23. https://doi.org/10.3324/haematol.2018.212845
Kuter DJ, Newland A, Chong B, Rodeghiero F, Romero M, Pabinger I, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: A subgroup analysis of integrated data from completed Romiplostim studies. Br J Haematol. 2019;3:503-13. https://doi.org/10.1111/bjh.15803
Ito S, Fujiwara S, Ikeda T, Toda Y, Mashima K, Umino K, et al. Evaluation of thrombotic events in patients with immune thrombocytopenia. Ann Hematol. 2020;99:49-55. https://doi.org/10.1007/s00277-019-03886-6
Janssens A, Rodeghiero F, Anderson D, Chong B, Boda Z, Pabinger I, et al. Changes in bone marrow morphology in adults receiving Romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Ann Hematol. 2016;95:1077-108. https://doi.org/10.1007/s00277-016-2682-2
Zaja F, Carpenedo M, Barate C, Borchiellini A, Chiurazzi F, Finazzi G, et al. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Realworld recommendations. Blood Rev. 2020;41:100647. https://doi.org/10.1016/j.blre.2019.100647
Cooper N, Hill Q, Grainger J, Westwod J, Bradbury C, Provan D, et al. Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: Results from a modified Delphi Panel. Acta Haematol. 2021;144:418-26. https://doi.org/10.1159/000510676
Neunert C, Terrel D, Arnold D, Buchanan G, Cines D, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829-66. https://doi.org/10.1182/bloodadvances.2019000966
Lino M, Sakamoto Y, Sato T. Treatmentfree remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: An observational retrospective analysis in realworld clinical practice. Int J Hematol. 2020;112:159-68. https://doi.org/10.1007/s12185-020-02893-y
Copyright (c) 2024 Biomedica
This work is licensed under a Creative Commons Attribution 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
